Technical Data
GRO gamma, Recombinant, Mouse (Chemokine, C-X-C Motif Ligand 3, CXCL3, CINC-2b, GRO3, GROg, Growth-regulated Protein gamma, Macrophage Inflammatory Protein 2-beta Precursor, MGSA gamma, MIP-2b, MIP2B, SCYB3)
Growth Factors, Cytokines Storage: -20°CShipping: Blue Ice
CXCL3 is also known as MIP­2 (macrophage inflammatory protein 2 beta), or DCI P­1 (dendritic cell inflammatory protein­1) in mouse, CINC2 (cytokine­induced neutrophil attractant 2) in rat, and GRO­ (growth­regulated oncogene gamma) in humans (1, 2) . It is an 8kD proinflammatory member of the CXC subfamily of heparin­binding chemokines, also called alpha chemokines (1­4) . The Glu­Leu­Arg (ELR) motif near the CXCL3 N­ terminus confers angiogenic properties and distinguishes it from interferon­inducible ELR­ CXC chemokines, which are angiostatic (4). ELR+ and ELR­ chemokines use CXCR2 and CXCR3 receptors, respectively (3, 4). Mature mouse CXCL3 shares 88% and 57% amino acid (aa) sequence identity with rat and human CXCL3, respectively. Among mouse ELR+ chemokines, it shares 82% aa sequence identity with CXCL2/GRO­ / MIP­2 and 34% ­ 58% with CXCL1/GRO­ / KC, CXCL5/ENA­78 and CXCL7/NAP­2. Due to their similar sequence and activity, CXCL2 and CXCL3 are sometimes referred to collectively as CXCL2/ 3, but are separate gene products (4 ­ 6). Mouse CXCL3 expression is induced in macrophages and early in maturation of DC by bacterial products such as lipopolysaccharides, and other inflammatory mediators (1, 7) . It is chemotactic for CXCR2­expressing neutrophils, helping to recruit them to areas of inflammation (1, 7). ELR+ chemokines also elicit endothelial cell chemotaxis, stimulating angiogenesis and playing a role in tumor development (3, 4). ELR+ chemokines upregulated by ischemi a play a role in ischemia­reper fusion injury (5, 6) . A decoy receptor , DARC (Duffy antigen receptor for chemokines) competes with CXCR2 for ELR+ chemokine binding, thus downregulating their effect (8). Neutrophil influx may also be downregulated by MMP­12, which has been found to inactivate CXCL3 and other ELR+ chemokines by cleaving them at the ELR site (9).

Source: E. coli-derived Ala28 Ser100 Accession# AAI17017

N-terminal Sequence Analysis: Ala28

Predicted Molecular Mass: 7.9kD
SDSP-AGE: 6.5kD, reducing conditions

Measured by its ability to chemoattract human CXCR2 transfected BaF3 mouse proB cells.
The ED50 for this effect is typically 25-100ng/ml.

Endotoxin: 1.0 EU per 1ug of the protein by the LAL method.

Other applications not tested.

Recommended Dilution:
Optimal dilutions to be determined by the researcher.

Storage and Stability:
12 months from date of receipt, 20 to 70°C as supplied.
1 month, 2 to 8°C under sterile conditions after reconstitution.
3 months, 20 to 70°C under sterile conditions after reconstitution.
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
Purity: 95% by SDS­PAGE under reducing conditions and visualized by silver stain.
Concentration: As reported
Form: Lyophilized from a 0.2um filtered solution in PBS with BSA as a carrier protein.
Specificity: Recognizes mouse CXCL3.

Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications without the expressed written authorization of United States Biological.
1. Nolan, K. F. et al . (2004) J. Immunol. 172:2201. 2. Modi, W. S. and T. Yoshimura (1999) Mol. Biol. Evol. 16:180. 3. Vandercappel l en, J. et al . (2008) Cancer Lett. 267:226. 4. Strieter, R.M. et al . (2005) Cytokine Growth Factor Rev. 16:593. 5. Nesmelova, I. V. et al . (2008) J. Biol. Chem. 283:24155.
6. Maheshwari, A. et al . (2004) Fetal Pediatr. Pathol. 23:145. 7. Furui chi , K. et al . (2008) Front. Biosci. 13:4021. 8. Takano, K. and H. Nakagawa (2001) Inflamm. Res. 50:503. 9. Horton, L. W. et al . (2007) Cancer Res. 67:9791.

Intended for research use only. Not for use in human, therapeutic, or diagnostic applications.